PT010 significantly reduced rate of moderate or severe COPD exacerbations in ETHOS trial

This article was originally published here

Compared with glycopyrronium/formoterol fumarate, PT010 achieved a 24% reduction (p<0.001) in exacerbations. PT010 achieved a 13% reduction (p=0.003) compared with PT009 (budesonide/formoterol fumarate). The dual-combination therapies used as

The post PT010 significantly reduced rate of moderate or severe COPD exacerbations in ETHOS trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply